Start of Phase I clinical trial of monalizumab in combination with durvalumab
Fourth clinical trial opened with monalizumab (IPH2201)
Opening of the Phase I/II trial of IPH2201 in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia
First patient treated in phase I/II trial with IPH2201 in ovarian cancer
Clearance of co-development and commercialization agreement with AstraZeneca and receipt by Innate Pharma of $250m initial payment
Innate Pharma and AstraZeneca announce global co-development and commercialisation agreement for IPH2201 in immuno-oncology
Innate Pharma collaborates with NCIC Clinical Trials Group on the phase I/II trial of IPH2201 in ovarian cancer
First Phase II trial with IPH2201 open in head and neck cancer
R&D Update on April 10, 2014 in New York
Innate Pharma acquires full rights to ANTI-NKG2A checkpoint inhibitor from Novo Nordisk A/S
